Menu
Not yet recruiting NCT07662226

Taste Acceptance and Effectiveness of Hyaluronic Acid and Chlorhexidine Mouthwashes in Children With Gingivitis

Phase I Interventional Plaque Induced Gingival Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Hyaluronic Acid mouthwash, Chlorohexidine 0.12% mouthwash.
Who it may be relevant to
Registry conditions: Plaque Induced Gingival Disease. Basic parameters: 8 years — 10 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Taste Acceptance and Clinical Effectiveness of Hyaluronic Acid Versus Chlorhexidine Mouthwashes in Children With Plaque-Induced Gingivitis: A Randomized Controlled Trial

Overview

This randomized controlled clinical trial aims to compare the taste acceptance and clinical effectiveness of hyaluronic mouthwash and chlorhexidine mouthwash in children with plaque-induced gingivitis. Clinical outcomes will be assessed using gingival and plaque indices, while taste acceptance will be evaluated using a validated hedonic scale. The findings may help identify a mouthwash that is both effective and acceptable to children, thereby improving adherence to oral hygiene practices.

Detailed description

This study is a randomized, single-blind, controlled clinical trial designed to compare the taste acceptance and clinical effectiveness of a hyaluronic acid mouthwash and a chlorhexidine mouthwash in children aged 8 to 10 years with plaque-induced gingivitis.

Eligible participants will be recruited from the outpatient clinic and screened according to the study eligibility criteria. After obtaining informed consent from parents or legal guardians and assent from the children, baseline clinical assessments will be performed. Gingival inflammation will be evaluated using the Loe and Silness Gingival Index, and dental plaque accumulation will be assessed using the Silness and Loe Plaque Index.

Participants will be randomly assigned in a 1:1 ratio to one of two intervention groups. The intervention group will receive a hyaluronic acid mouthwash, while the control group will receive a chlorhexidine mouthwash. Allocation concealment will be maintained using sealed opaque envelopes prepared by an independent investigator. Clinical outcome assessment will be performed by a blinded examiner who will remain unaware of group allocation throughout the study period.

All participants will receive standardized oral hygiene instructions and identical instructions regarding mouthwash use. Participants will be instructed to use the assigned mouthwash twice daily for 14 days in addition to their routine toothbrushing practices.

Taste acceptance will be evaluated as the primary outcome using a validated facial hedonic scale following mouthwash use. Secondary outcomes will include changes in gingival inflammation and plaque accumulation, as measured by the Loe and Silness Gingival Index and the Silness and Loe Plaque Index, respectively.

Follow-up clinical examinations will be conducted after 14 days of intervention. Compliance with mouthwash use and any adverse events will be documented throughout the study period. The study aims to determine whether hyaluronic acid mouthwash provides comparable clinical effectiveness to chlorhexidine while demonstrating greater taste acceptance among children with plaque-induced gingivitis.

Interventions

  • Drug Hyaluronic Acid mouthwash
    Q-Afta®, CIRA Pharma, Egypt
  • Drug Chlorohexidine 0.12% mouthwash
    Hexitol®, 0.12% chlorhexidine gluconate; Arab Drug Company

Primary outcome measures

  • Taste acceptance [Time frame: After 14 days of mouthwash administeration]
Secondary outcome measures (2)
  • Gingival index [Time frame: At baseline before the study and after 14 days]
  • Plaque index [Time frame: At baseline before the study and after 14 days]

Eligibility criteria

Inclusion criteria

  • Children aged from 8-12 years of both sexes.
  • Children with a history of bleeding on brushing typical signs and symptoms of gingivitis.
  • Healthy child (ASA I).
  • Eruption of upper and lower permanent central and lateral incisors.
  • Parent's agreement to sign the informed consent.
  • Parent's ability for attending follow up visits.

Exclusion criteria

  • Children -allergic to Chlorhexidine or Hyaluronic acid.
  • Children with special health care needs or having a history of serious systemic disease that may affect the gingival health.
  • Use of Systemic NSAIDs, steroids, or antibiotics within a month before the study.
  • Children undergoing orthodontic treatment or having an intra-oral prosthesis.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Faculty of dentistry, Cairo university — Cairo

Identifiers

NCT: NCT07662226 · Mouthwashes for children-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗